|
Array asthma drug meets main goal in mid-stage study
Reuters (Reuters) – Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose as much as 19 percent to $6.64 — their highest … |
View full post on asthma – Google News